An advertised medicine name is not a complete description of treatment. That distinction matters at Bliv, which promotes semaglutide and tirzepatide through an online intake process while leaving important product details unresolved in its public documentation. Its materials explain who handles clinical decisions, how prescriptions move to a pharmacy, and when charges become nonrefundable. They do not establish the formulation, administration route, concentration, or supply quantity a particular patient would receive.
This review separates documented service terms from promotional claims and clinical evidence. The consulted pages describe a U.S. telehealth platform operated by Metabody Services, LLC, with care provided through separate medical groups. They were consulted October 19, 2026; the terms and policies reviewed identify October 15, 2026, as their effective date. The central question is not whether semaglutide and tirzepatide have research behind them, but how much that research can establish about an unspecified product obtained through this particular service.
At a glance
- Platform versus medical care
- Metabody Services, LLC operates Bliv as a technology and management business; Metabody Medical P.A. and affiliated professional entities are responsible for clinical services.Sources: [7]
- Conditional advertised prices
- Semaglutide is advertised as low as $116 per month and tirzepatide as low as $199 per month, each depending on plan structure and eligibility. These are not established all-in prices.Sources: [5]
- Compounded-product disclosure
- The commercial page describes medications as compounded; the terms say some medications may be compounded. Neither establishes the exact preparation for an individual order.
- Medication refund boundary
- The terms allow a full medication-order refund before the prescription is transmitted to the pharmacy, but generally make it nonrefundable after transmission.Sources: [7]
- Clinical evidence boundary
- Compounded preparations are not FDA approved. FDA recommends them when an individual’s medical needs cannot be met by an approved drug; this is not a provider-specific efficacy assessment.Sources: [1]
Start with the product, not the ingredient name
Bliv’s commercial page says medications prescribed through the service are compounded and dispensed by licensed U.S. pharmacies under valid prescriptions. Its terms are narrower: some medications may be compounded and prepared by a state-licensed compounding pharmacy for an individual prescription. These statements point toward compounded treatment but do not settle what every order contains. The distinction should be resolved before payment, rather than assuming the broader advertisement or narrower contract fully describes a proposed prescription.
The public documentation does not confirm administration route, presentation, concentration, added ingredients, or supply quantity for either advertised medicine. Nor does it name the pharmacy that would handle a particular order. Those omissions limit the connection a reader can draw between a familiar ingredient name and published research. Our guide to formulation and route explains why these details are evidence questions, not merely packaging preferences.
Bliv’s terms say the clinician will prescribe a compounded medication only when clinically appropriate and discuss the reasons with the patient. FDA separately recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug. Compounded preparations do not receive FDA premarket review for safety, effectiveness, and quality. That does not, by itself, establish clinical inequivalence—or validate the specific preparation offered. Approval attaches to a particular drug product, not to a telehealth platform.
| Documented statement | What it establishes | What remains unresolved |
|---|---|---|
| Semaglutide advertised | An ingredient-level offering | Exact formulation, route, concentration, and quantity |
| Tirzepatide advertised | An ingredient-level offering | Exact formulation, route, concentration, and quantity |
| Commercial page describes compounded medicines | A disclosed compounded-treatment pathway | Whether every individual order follows that description |
| Terms identify pharmacy partners | A pharmacy fulfillment arrangement | The pharmacy assigned before an individual order |
| Pharmacy details appear on label and order | A documented identification point | Whether those details are available before payment |
Research supports specific treatments, not Bliv’s performance
Bliv markets semaglutide as a proven option for steady weight loss and tirzepatide with language including “Often faster results.” Those are provider claims, not independently measured outcomes for Bliv patients. The consulted documentation does not establish a provider-specific average weight change, treatment persistence rate, or adverse-event rate. Its descriptions therefore cannot answer how people using its actual preparations fare over time, or how consistently patients receive follow-up.
Published studies answer narrower questions. STEP 1 studied a particular subcutaneous semaglutide regimen in adults without diabetes; SURMOUNT-1 studied particular subcutaneous tirzepatide regimens in adults without diabetes. Neither was a trial of Bliv or its compounded products. Their findings cannot automatically be transferred to different formulations, routes, or unspecified preparations. Readers can use our explanation of why clinical trials are not company performance reports to keep those categories separate.
This does not make the research irrelevant. It makes product identification essential to interpreting it. Bliv’s marketing comparison should not be treated as a randomized head-to-head comparison, and neither ingredient’s research predicts an individual result. A useful consultation would connect the proposed product to the evidence the clinician considers relevant, explain the remaining uncertainties, and distinguish expected benefits from advertising shorthand.
Who is responsible for the medical decision?
The contractual operator is Metabody Services, LLC, using the Bliv brand. Its terms explicitly describe it as a technology and management company, not a healthcare provider, and say it does not employ or control the treating clinicians’ clinical judgment. Evaluations, diagnoses, treatment plans, prescriptions, laboratory orders, refills, and follow-up belong to Metabody Medical P.A. and its affiliated professional entities, collectively described as the Medical Groups.
The terms assign separate entities to California, Kansas, Colorado, and Texas, and one entity to New Jersey and New York. Metabody Medical P.A. is listed for other states. This organizational map is not a guarantee of nationwide appointment availability: clinical services are offered only where the groups have licensed clinicians, and Bliv reserves the ability to restrict, suspend, or discontinue services by state. The documentation’s credential and licensing statements were not independently verified for this review.
Platform use requires being at least 18, able to form a binding contract, and both resident in and physically located in the United States. Those are service-access conditions, not complete medical eligibility criteria. The consulted materials do not provide a full GLP-1 screening policy or exclusion list. Patients must also consent to telehealth and acknowledge the medical groups’ privacy notice, although the linked consent’s state-specific provisions were not available for evaluation.
From intake to follow-up: documented steps and open questions
Bliv promotes a medical intake reviewed by a U.S.-licensed provider without a phone call or video visit. It says a licensed clinician reviews health answers and, when appropriate, usually writes a prescription within a day. The terms place important limits on that streamlined description: requesting a service guarantees neither acceptance nor evaluation, prescription, or outcome. A clinician can request additional information, laboratory testing, or an in-person visit, or decline or discontinue treatment.
Where testing is ordered, the terms say an independent CLIA-certified laboratory performs it and sends results through the platform and to the clinician. The documents do not establish which tests a particular patient would need or which charges a plan includes. Bliv also promises individualized assessments and ongoing clinical support, but does not specify follow-up frequency, clinical response times, or the requirements for prescription renewal.
The advertised Skool community offers dietitian-led nutrition guidance and a user forum; its cost is not clarified in the consulted passage. Community access should not be assumed to substitute for individual clinical review. NIDDK describes follow-up as a question of treatment response and tolerability, not simply continued payment. Before enrollment, ask how routine check-ins, side-effect questions, and refill decisions are handled, using our clinical follow-up guide as preparation.
The advertised dollar amounts answer different questions
Bliv displays semaglutide “as low as” $116 per month and tirzepatide “as low as” $199 per month, both conditional on plan structure and eligibility. A separate headline offers a GLP-1 consultation starting as low as $58 per month. The documentation does not reconcile these amounts or identify the product, supply, or purchasing arrangement behind the headline. A limited-time 50% discount also appears without enough detail to establish the reference price, eligible product, or promotion duration.
Financing is advertised as low as $29 per month for eligible plans, alongside CareCredit at 0% for 24 months and Klarna split payments. These are advertised payment alternatives, not evidence that $29 buys a month of medication. The financed principal and complete repayment amount are not established. Although the promotion includes “Instant approval” language, eligibility and plan conditions still matter; the documentation does not establish that every applicant qualifies.
The terms place prices, billing frequency, renewals, and inclusions at the point of purchase. They distinguish subscriptions, one-time purchases, clinical charges, and prescription charges. Consequently, neither total treatment cost nor an evaluation fee, included tests, supplies, or prepayment requirements can be determined here. Services and medicines are self-pay; absent an express statement otherwise, the operator and medical groups do not bill insurance, Medicare, or Medicaid. Possible reimbursement or HSA/FSA use is not guaranteed.
Cancellation and refunds operate on separate tracks
Bliv advertises no long-term commitments or cancellation fees, but paid subscriptions automatically renew at the then-current price until canceled. Cancellation is available through account settings, applicable app-store subscription controls, or support. It takes effect at the end of the current billing period, with access continuing until then. Crucially, canceling the subscription does not itself cancel a pending prescription order, laboratory order, or clinical appointment.
Already charged subscription fees, program fees, and AI credits generally are neither refunded nor prorated, subject to legal requirements or purchase-specific exceptions. The terms promise unused prepaid amounts back if Bliv terminates an account without cause or withdraws a paid service from a state. Evaluation fees follow another rule: a full refund applies if the clinician declines treatment or determines the person is not a candidate; an evaluation completed with treatment offered is generally nonrefundable.
Medication is not charged until a clinician approves a prescription. A medication order can be canceled for a full refund before transmission to the pharmacy; after transmission it is nonrefundable under the stated policy. That cutoff can precede shipment, so shipment status alone is not the right cancellation test. Approved refunds are issued to the original payment method within 10 business days, which does not guarantee the receiving bank posts the money within that period.
Pharmacy fulfillment and delivery require a closer look
The terms say prescriptions are filled through licensed U.S. pharmacies or outsourcing facilities selected by the Medical Groups. These pharmacy partners are independent of Metabody Services, LLC, and dispensing is subject to their terms and state pharmacy law. Dispensing does not necessarily identify who compounded a preparation. For compounded medication, Bliv says the preparing pharmacy’s name and contact information appear on the prescription label and in the order details.
Bliv advertises free shipping, discreet packaging, and shipment to the patient’s door, typically within three to five days. The wording does not clearly establish when that clock starts or whether the interval denotes dispatch or arrival. It is separate from the usually-one-day clinical review claim, and neither is a guaranteed individual timeline. The terms limit shipments to the provided U.S. address and assign patients responsibility for accurate details, receipt, and proper storage.
The terms disclaim responsibility for delays or damage caused by carriers, weather, or handling after delivery. Separately, prescription products cannot be returned, but damaged, incorrect, or unusable shipments reported within seven days qualify for a no-charge replacement under the terms. The supplied text does not explain how the liability disclaimer and replacement promise interact. If the pharmacy cannot fill the prescription, the stated options are a full medication-charge refund or a clinician-approved alternative. For an injectable GLP-1 product that arrives warm or insufficiently refrigerated, FDA explicitly advises not using it and contacting the provider or pharmacy. The delivery and cold-chain guide explains why logistics claims need separate scrutiny.
Support, records, and AI have different roles
Bliv advertises phone support, and its terms publish 888-859-2882 and a mailing address at 2943 Parkway Blvd, Unit 374, West Valley City, UT 84119. Support hours and clinician response times are not established. Email addresses were masked in the consulted text, so this review cannot provide a verified email contact. The terms also say the English-language version controls; Spanish-language care, interpretation, and clinical documents were not confirmed.
The AI assistant is expressly informational: it does not provide medical advice, diagnose, treat, prescribe, or make clinical decisions. Its availability therefore does not establish access to a treating professional. Bliv’s privacy policy says identifiable personal information, including health information and AI conversations, is not used to train AI models; it permits de-identified data to be used to evaluate and improve its own models and features.
The medical privacy notice says most records are available through the Bliv account. Additional copies can be requested from the Privacy Officer, with a response within 30 days and one possible 30-day extension with notice; reasonable cost-based copying fees may apply. Those are useful documented access provisions, but they do not resolve how quickly a patient can reach a clinician about an active concern. Before purchasing, distinguish administrative support, AI responses, community discussion, and clinical communication.
Questions & answers
Does Bliv guarantee a prescription after the online intake?
No. Bliv advertises review usually within a day, but its terms allow clinicians to decline treatment, request more information or tests, require an in-person visit, or discontinue care. The no-phone-call, no-video description is a marketed intake pathway, not a promise that every case can be completed without additional evaluation. Ask how any additional requirements affect timing and charges.
Is Bliv’s $58 monthly headline the semaglutide price?
The documentation does not establish that connection. The headline says a GLP-1 consultation starts as low as $58 per month, while the semaglutide listing says as low as $116 per month, conditional on plan structure and eligibility. Before paying, request the exact product, first charge, subsequent charges, billing interval, included services, and any required upfront payment. The advertised figures alone do not establish a complete purchase.
Can I identify the pharmacy before receiving medication?
Bliv says the preparing pharmacy’s name and contact details appear on the prescription label and in order details. It does not name the pharmacy for a prospective individual order in the consulted documentation. Ask whether that information can be provided before the prescription is transmitted, together with the exact formulation and presentation. Transmission matters because it is also the stated medication-refund cutoff.
Does canceling Bliv stop a pending medication order?
Not automatically. Subscription cancellation takes effect at the end of the billing period and does not itself cancel pending prescriptions, laboratory orders, or appointments. Medication cancellation must be handled separately before pharmacy transmission to qualify for the stated full refund. If treatment has already been offered after a completed evaluation, the evaluation charge is generally nonrefundable even when the medication order remains cancelable.
What should I do about a damaged or warm shipment?
Bliv’s terms require reporting damaged, incorrect, or unusable shipments within seven days for a no-charge replacement. Separately, FDA advises not using an injectable GLP-1 medicine that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. The consulted Bliv documents do not specify cold-chain procedures, so ask about storage instructions, shipment-condition concerns, and the correct reporting channel rather than assuming packaging appearance settles usability.
Does Bliv accept insurance or guarantee HSA/FSA eligibility?
Its terms describe clinical services and prescriptions as self-pay. Unless expressly stated otherwise, neither the operator nor the medical groups bill private insurance, Medicare, or Medicaid. The terms allow that reimbursement or HSA/FSA use may be possible but make no eligibility representation. That is not a statement that every government-insured person is excluded from using the service; it describes the documented billing arrangement.
Our assessment
Bliv provides meaningful documentation about its division of responsibilities, clinician discretion, subscription renewal, and separate evaluation and medication refund rules. Those details make its service more understandable than the promotional prices alone would suggest. The evidence is less complete where it matters most for connecting treatment to research: the exact product, route, concentration, quantity, assigned pharmacy, and follow-up schedule remain unresolved for an individual order. Its advertised monthly amounts also do not establish total cost. A reasonable next step for someone considering the service is to request a written product description and itemized purchase terms before authorizing payment or pharmacy transmission. Bliv’s documents establish a prescribing and fulfillment framework, not independently verified clinical performance. Whether that framework meets a particular person’s needs depends on the clinical discussion and transaction details that the public materials leave open.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Bliv — get a glp 1 prescription ↗
- Bliv — privacy ↗
- Bliv — terms ↗
- Bliv — notice of privacy practices ↗